Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition
Year: 2025
Type: article
Abstract: None.
DOI: 10.1002/ctm2.70535
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,470
Funder: Health and Medical Research Fund
Award: G6815276962
OpenAlex ID: W4416420344
